CN117615763A - 磷酸肌醇3激酶β抑制剂及其组合物和制备方法 - Google Patents

磷酸肌醇3激酶β抑制剂及其组合物和制备方法 Download PDF

Info

Publication number
CN117615763A
CN117615763A CN202280017243.9A CN202280017243A CN117615763A CN 117615763 A CN117615763 A CN 117615763A CN 202280017243 A CN202280017243 A CN 202280017243A CN 117615763 A CN117615763 A CN 117615763A
Authority
CN
China
Prior art keywords
alkyl
compound
substituted
morpholino
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280017243.9A
Other languages
English (en)
Chinese (zh)
Inventor
赵景
王�琦
喻向阳
程辉敏
张佩宇
林志雄
方磊
马松龄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Jingtai Technology Co Ltd
Jiandao Biopharmaceutical Co ltd
Original Assignee
Shenzhen Jingtai Technology Co Ltd
Jiandao Biopharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Jingtai Technology Co Ltd, Jiandao Biopharmaceutical Co ltd filed Critical Shenzhen Jingtai Technology Co Ltd
Publication of CN117615763A publication Critical patent/CN117615763A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN202280017243.9A 2021-02-01 2022-01-25 磷酸肌醇3激酶β抑制剂及其组合物和制备方法 Pending CN117615763A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163144287P 2021-02-01 2021-02-01
US63/144,287 2021-02-01
PCT/US2022/013725 WO2022164812A1 (en) 2021-02-01 2022-01-25 Phosphoinositide 3 kinase beta inhibitors and compositions and methods thereof

Publications (1)

Publication Number Publication Date
CN117615763A true CN117615763A (zh) 2024-02-27

Family

ID=82654889

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280017243.9A Pending CN117615763A (zh) 2021-02-01 2022-01-25 磷酸肌醇3激酶β抑制剂及其组合物和制备方法

Country Status (9)

Country Link
US (1) US20240166617A1 (cg-RX-API-DMAC7.html)
EP (1) EP4284375A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024508045A (cg-RX-API-DMAC7.html)
KR (1) KR20240016938A (cg-RX-API-DMAC7.html)
CN (1) CN117615763A (cg-RX-API-DMAC7.html)
AU (1) AU2022214080A1 (cg-RX-API-DMAC7.html)
CA (1) CA3209581A1 (cg-RX-API-DMAC7.html)
IL (1) IL304895A (cg-RX-API-DMAC7.html)
WO (1) WO2022164812A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3217937A1 (en) 2021-05-03 2022-11-10 Erin Danielle ANDERSON Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
MX2023013987A (es) 2021-05-27 2024-02-12 Petra Pharma Corp Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento contra el cáncer.
TW202329930A (zh) 2021-09-30 2023-08-01 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑
US20260130925A1 (en) * 2022-10-14 2026-05-14 Genesis Molecular Ai, Inc. Methods for treating cancer
EP4602043A1 (en) * 2022-10-14 2025-08-20 Genesis Therapeutics, Inc. 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer
EP4680612A1 (en) * 2023-03-15 2026-01-21 AN2 Therapeutics, Inc. Chemical compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1418195A (zh) * 2000-01-24 2003-05-14 基纳西亚股份有限公司 用于治疗的吗啉代基取代的化合物
CN102712615A (zh) * 2009-10-27 2012-10-03 阿斯利康(瑞典)有限公司 具有抗肿瘤活性的色烯酮衍生物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1537102A4 (en) * 2002-08-16 2010-12-08 Astrazeneca Ab INHIBITORS OF PHOSPHOINOSITIDE-3-KINASE BETA
WO2008148074A2 (en) * 2007-05-24 2008-12-04 Research Foundation Of State University Of New York Inhibitors of mtor and methods of treatment using same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1418195A (zh) * 2000-01-24 2003-05-14 基纳西亚股份有限公司 用于治疗的吗啉代基取代的化合物
CN102712615A (zh) * 2009-10-27 2012-10-03 阿斯利康(瑞典)有限公司 具有抗肿瘤活性的色烯酮衍生物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BERNARD BARLAAM: ""Discovery of (R)-8-(1-(3, 5-difluorophenylamino)ethyl)-N, N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kβ and PI3Kδ for the treatment of PTEN-deficient cancers"", 《JOURNAL OF MEDICINAL CHEMISTRY》, vol. 58, no. 2, 22 January 2015 (2015-01-22), pages 943 - 962 *
BERNARD BARLAAM: ""Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1, 2-a]pyrimidine-7-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours"", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》, vol. 24, 21 June 2014 (2014-06-21), pages 3928 - 3935 *
VICTOR CERTAL: ""Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers"", 《JOURNAL OF MEDICINAL CHEMISTRY》, vol. 57, no. 3, 13 February 2014 (2014-02-13), pages 903 - 920 *

Also Published As

Publication number Publication date
WO2022164812A1 (en) 2022-08-04
US20240166617A1 (en) 2024-05-23
CA3209581A1 (en) 2022-08-04
AU2022214080A1 (en) 2023-09-14
EP4284375A1 (en) 2023-12-06
IL304895A (en) 2023-10-01
KR20240016938A (ko) 2024-02-06
JP2024508045A (ja) 2024-02-21
EP4284375A4 (en) 2025-04-23

Similar Documents

Publication Publication Date Title
CN112368283B (zh) 含二并环类衍生物抑制剂、其制备方法和应用
WO2023109883A1 (zh) 一类芳杂环取代的化合物及其制备方法和用途
CN103930423B (zh) 吡唑并喹啉衍生物
WO2024125642A1 (zh) 含嘧啶多元并环类衍生物抑制剂、其制备方法和应用
WO2022161461A1 (zh) Sos1抑制剂及其制备方法和应用
WO2023041049A1 (zh) 作为sos1抑制剂的杂环化合物及其用途
CN116731044A (zh) 含嘧啶多环类生物抑制剂、其制备方法和应用
CN113166139A (zh) 作为HPK1抑制剂的吡咯并[2,3-b]吡啶及其用途
JP2021505553A (ja) 新規化合物及び疾患の治療のためのその医薬組成物
CN106336413B (zh) 作为jak抑制剂的化合物及其用途
KR102794736B1 (ko) 트리아졸로피리다진 유도체, 이의 제조 방법, 약물 조성물 및 용도
WO2025157246A1 (zh) 嘧啶多环类衍生物抑制剂、其制备方法和应用
KR20240016938A (ko) 포스포이노시티드 3 키나아제 베타 억제제 및 그 조성물 및 방법
WO2021115457A9 (zh) 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用
CN105777756A (zh) 杂芳化合物及其在药物中的应用
TW201605866A (zh) 可用作pim激酶抑制劑之呋喃并-及噻吩并-吡啶甲醯胺化合物
CN112292129A (zh) 用于治疗疾病的新化合物及其药物组合物
WO2021190417A1 (zh) 新型氨基嘧啶类egfr抑制剂
CN114127080B (zh) 作为激酶抑制剂的杂环化合物、包括该杂环化合物的组合物、及其使用方法
CN111683950A (zh) AhR调节剂
CN115873000A (zh) 异喹啉酮类及喹唑啉酮类化合物及其组合物和用途
EP4236950A1 (en) N-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
CN115677682B (zh) 螺环类plk4抑制剂及其用途
WO2024083111A1 (zh) 一种新型杂环化合物
CN120981466A (zh) 作为egfr抑制剂的大环氨基吡啶化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination